ISRCTN34134007进行中（未招募）未知
Scaling European citizen-driven transferable and transformative digital health: a multi-site effectiveness-implementation hybrid trial of the Digital Health Platform ProACT to support older adults managing multiple chronic health conditions (multimorbidity) in Europe
适应症
试验速览
- 阶段
- 未知
- 状态
- 进行中（未招募）
- 入组人数
- 2,220
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Participants with multimorbidity must:
- •1. Be aged 65 years old and over
- •2. Possess sufficient cognitive capacity to provide written informed consent
- •3. Have at least 2 of the following conditions: diabetes, chronic respiratory disease (e.g. chronic obstructive pulmonary disease (COPD), chronic asthma), chronic heart failure, chronic heart disease (e.g., coronary artery disease, cardiovascular disease (including hypertension, atherosclerosis, angina or arrhythmia))
- •For care network participants to be included, the person with multimorbidity must provide consent for their participation. Care network participants must:
- •1. Be aged 18-90 years old and over
- •2. Be providing support to a consented participant with multimorbidity in trial arm 1 (if they are an informal carer, they must be providing support to a participant with multimorbidity for at least six months; and if they are a formal carer, formal care Quality Assistant, or healthcare professional, they must be formally recognised as such and possess at least two years’ experience of professionally working in a relevant health or primary care setting with people with multimorbidity with the same health conditions as those involved in the current trial)
- •3. Have access to a tablet, smartphone, or computer with an internet connection
- •4. Possess the skills to use an internet-based application or website
- •5. Possess sufficient cognitive capacity to provide written informed consent
- •Partner organisation management and staff must:
- •1. Be aged 18 or older
- •2. Be overseeing and/or implementing the delivery of ProACT to their clients with multimorbidity
- •3. Have access to a tablet, smartphone, or computer with an internet connection
- •4. Possess the skills to use an internet-based application or website
排除标准
- •Does not meet inclusion criteria
研究者
相似试验
已完成
不适用
istening effort in the European population: A new innovative program of research and training10019243hearing lossHearing impairmentNL-OMON44463Vrije Universiteit Medisch Centrum171
已完成
2 期
A Prospective, Multicenter, European Registry Investigating the Lutonix Paclitaxel-Coated Balloon for the Treatment of In-Stent Restenosis within Bare-Metal Stentsrestenotic lesions - stenosis10011082NL-OMON33458utonix20
已完成
不适用
An European multi-centre, open-label, prospective, feasibility study evaluating the Nalu Alpha External Trial Stimulator for the treatment of chronic pain via Spinal Cord Stimulation (SCS)Spinal Cord Stimulation for pain control in patients with chronic pain.External Trial StimulatorR52.2Other chronic painDRKS00013981alu Medical, Inc.25
进行中（未招募）
不适用
SEQUENTIAL THERAPY WITH TACROLIMUS AND RITUXIMAB IN PRIMARY MEMBRANOUS NEPHROPATHYPrimary membranous nephropathyMedDRA version: 17.0Level: LLTClassification code 10027170Term: Membranous nephropathySystem Organ Class: 100000004857EUCTR2013-000226-55-NLFundacion Renal Iñigo Alvarez Toledo175
进行中（未招募）
不适用
An open-label, two-step, multicenter European study to evaluate the efficacy and safety of Sandostatin LAR at High Dose or in combination either with GH-receptor antagonist or dopamine-agonist in acromegalic patients not adequately controlled by conventional regimen - NDMedDRA version: 9.1Level: LLTClassification code 10000599Term: AcromegalyacromegalyEUCTR2005-005852-42-ITOVARTIS FARMA100